PTPRC and breast cancer: While there was no significant alteration of total CD45+ leukocytes in the peripheral blood after the first cycle of treatment (Supplementary Figure S2a), BC patients who responded to treatment with a positive fold-change in their granulocyte population had an average duration of treatment response of 49.2 ± 11.9 months (Supplementary Figure S2b).